Bingham Kate's Form 4/A amendment
AmendedBicycle Therapeutics PLC (BCYC) · filed Jul 20, 2021
- Accession no.
- 0000899243-21-028984
- Filed
- Jul 20, 2021
- Trade date
- Jul 13-14, 2021
- Filing delay
- 7 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Jul 15, 2021
This filing lists 4 non-derivative transactions. Open-market sales total $1.53M. It was filed 7 days after the trade.
This amendment replaces 0000899243-21-028546 (filed Jul 15, 2021).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bingham KateCIK 0001185040 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 13, 2021 | Ordinary Shares | SSaleDisposed | −588 | $33.50 | −$19,698 | 1,875,049 | Indirect | |
| Jul 14, 2021 | Ordinary Shares | SSaleDisposed | −43,378 | $34.01 | −$1,475,285.78 | 1,831,671 | Indirect | |
| Jul 13, 2021 | Ordinary Shares | SSaleDisposed | −12 | $33.50 | −$402 | 39,625 | Indirect | |
| Jul 14, 2021 | Ordinary Shares | SSaleDisposed | −917 | $34.01 | −$31,187.17 | 38,708 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
- F2
These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.
- F3
These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
- F4
These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.
Remarks
The original Form 4 filed on July 15, 2021 is amended by this Form 4 amendment to reflect Ms. Bingham's resignation from the Board of Directors effective as of the Annual Meeting held on June 28, 2021. As a result of her resignation, Ms. Bingham is no longer subject to Section 16 reporting requirements.